Immunocore to Present at Annual Healthcare Conference

Got story updates? Submit your updates here. ›

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering transformative immunomodulating medicines, announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference. The company's management team will present a fireside chat on April 13, 2026, providing an overview of Immunocore's pipeline and progress.

Why it matters

As a leader in the development of novel T-cell receptor (TCR) based immunotherapies, Immunocore's participation in this high-profile healthcare investment conference will allow the company to showcase its innovative platform and clinical programs to a wide audience of investors and industry stakeholders.

The details

Immunocore, headquartered in Oxfordshire, England, with U.S. operations in Radnor, Pennsylvania, and Gaithersburg, Maryland, is pioneering a new class of TCR bispecific immunotherapies called ImmTAX. These therapies are designed to treat a broad range of diseases, including cancer, autoimmune disorders, and infectious diseases. The company's lead oncology product, KIMMTRAK, has already been approved for the treatment of unresectable or metastatic uveal melanoma in several major markets.

• The 25th Annual Needham Virtual Healthcare Conference will take place on April 13, 2026.
• Immunocore's fireside chat presentation is scheduled for 3:00 p.m. EDT on April 13, 2026.

What’s next

Following the conference, a replay of Immunocore's presentation will be made available on the company's website for a limited time.